(RxWiki News) The US Food and Drug Administration (FDA) has approved a new fast-acting medication to treat migraines.
This new medication is the first fast-acting, orally disintegrating tablet of its drug class. This new approval, found under the brand name Nurtec ODT and active ingredient rimegepant, is approved to treat adults with migraines with or without aura.
Rimegepant is not approved to prevent migraines.
This medication belongs to the drug class calcitonin gene-related peptide (CGRP) receptor antagonist. The recommended dose is 75 mg once a day as needed.
The tablet is simply placed on or under the tongue. No water or drink is needed because the tablet will dissolve and start working within minutes.
A common side effect of Nurtec ODT is nausea.
This medication will be available in pharmacies in early March, according to the manufacturer (Biohaven).
Speak with your health care provider if you have any questions.
